title: [Gastric adenocarcinoma with lymphoid stroma. About nine cases].
abstract: OBJECTIVE
  the purpose of this work is to study the pathological features and the outcome of lymphoid stroma gastric carcinoma and its relation with Epstein-Bar Virus (EBV) and the imortance of the EBV serology in detection of early reccurence.
  
  
  METHODS
  between january 1990 and december 2004, 155 patients underwent gastric resection for gastric carcinoma. Nine of them had lymphoid stroma gastric carcinoma. Over all survival as well as disease free survival were determined. Detection of reccurence was based on clinical exam and on findings yielded by endoscopy, radiological exams and EBV serology. A comprison of survival rate of patients beteween current gastric carcinoma and those with lymphoid stroma gatsric carcinoma was done using the Log Rank test.
  
  
  RESULTS
  the patients (7 men and 2 women) had a mean age of 61 years (41 to 82). The tumor was in the antrum in 4 cases, in the body of the stomach in 3 cases and in the cardia in 2 cases. The mean tumor size was 8 cm with deep invasion of the stomach wall in 5 cases and ganglionnary invasion in 6 cases out of 9. EBV was detected in all patients by in situ hybridation. Post operative morbidity and mortality were nil. Global survival and disease free survival were, respectively, 53.3% and 65.6% in lymphoid stroma gatsric carcinoma, and 43.4% and 63.5% for current gatsric carcinoma. Three patients died of a reccurent disease after 6, 30 and 33 months. The remaing 6 patients didn't have signs of reccurence.
  
  
  CONCLUSIONS
  lymphoid stroma gastric carcinoma is a bulky, local disease. In our patients, it was always associated with EBV. Over all survival was better than survival of current gastric carcinoma, although there was no significance. EBV serology can be an effective screening procedure of reccurence.
authors.affiliation: Service de Chirurgie Générale et Digestive A. La Rabra, 1007, Tunis.
authors.forename: Fadhel
authors.initials: F
authors.lastname: Ftériche
authors.forename: Tarek
authors.initials: T
authors.lastname: Bouzid
authors.forename: Amin
authors.initials: A
authors.lastname: Makni
authors.forename: Rachid
authors.initials: R
authors.lastname: Ksantini
authors.forename: Haykel
authors.initials: H
authors.lastname: Bdioui
authors.forename: Faouzi
authors.initials: F
authors.lastname: Chebbi
authors.forename: Mohamed
authors.initials: M
authors.lastname: Jouini
authors.forename: Adel
authors.initials: A
authors.lastname: Ammous
authors.forename: Montasser
authors.initials: M
authors.lastname: Kacem
authors.forename: Zoubeir
authors.initials: Z
authors.lastname: Ben Safta
mesh_terms: D000230:Adenocarcinoma / Q000473:pathology* / Q000821:virology; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D004854:Herpesvirus 4, Human / Q000302:isolation & purification; D006801:Humans; D008221:Lymphoid Tissue / Q000473:pathology; D008297:Male; D008875:Middle Aged; D013274:Stomach Neoplasms / Q000473:pathology* / Q000821:virology